Published in Vaccine Weekly, February 19th, 1996
Widespread publicity about the first vaccinees to become infected was a major factor in the previous cancellation of large-scale Phase III efficacy trials of the Genentech and Chiron gp120 vaccines.
Now John P. Moore of the Aaron Diamond Research Center, New York City, reports that 19 participants in Phase I/II vaccine trials developed HIV infection. Although two of the individuals received placebo vaccinations, 14 of the subjects had received a full course of three or four immunizations before becoming...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly